FDA
-
-
-
-
-
-
-
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
-
-
-
-
-
-
-
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
-
-
-
-
-
-
-
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
-
-
-
-
-
-
-
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
-
-
-
-
-
-
-
RenovoRx names Mark Voll as chief financial officer
-
-
-
-
-
-
-
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
-
329,914 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

